Adams P C, Sloan P, Morley A R, Holt D W
Br J Clin Pharmacol. 1986 Dec;22(6):736-8. doi: 10.1111/j.1365-2125.1986.tb02968.x.
In 14 patients receiving chronic amiodarone therapy the appearance of multilamellar inclusion bodies in peripheral blood neutrophils was related to both plasma concentrations of amiodarone and its desethyl metabolite and unwanted effects of the drug. Seven of the patients had well defined inclusion bodies. In this group mean amiodarone and desethylamiodarone concentrations were significantly higher than in the remaining seven patients and all but one had unwanted effects of the drug. Of the seven patients without inclusion bodies only one, with high plasma amiodarone and desethylamiodarone concentrations, had unwanted effects of the drug. It is concluded that the appearance of multilamellar bodies in the blood neutrophils of amiodarone-treated patients may help to distinguish those patients at risk of long-term amiodarone toxicity.
在14例接受慢性胺碘酮治疗的患者中,外周血中性粒细胞中多板层包涵体的出现与胺碘酮及其去乙基代谢产物的血浆浓度以及该药物的不良反应均有关。7例患者有明确的包涵体。在这组患者中,胺碘酮和去乙基胺碘酮的平均浓度显著高于其余7例患者,除1例患者外,其余患者均有该药物的不良反应。在7例无包涵体的患者中,只有1例血浆胺碘酮和去乙基胺碘酮浓度较高的患者出现了该药物的不良反应。得出的结论是,胺碘酮治疗患者血液中性粒细胞中多板层小体的出现可能有助于区分那些有长期胺碘酮毒性风险的患者。